Elucid is a Boston-based medical technology company using uniquely interpretable and validated AI to provide physicians with a cost-effective means to optimize treatment decisions for patients with known or suspected cardiovascular disease. Advanced clinical insights from ElucidVivo equip physicians with critical information designed to enable precision medicine. ElucidVivo is the first FDA-Cleared and CE-marked non-invasive software to quantify atherosclerotic plaque characteristics compared to histopathology, including Lipid Rich Necrotic Core.
| Date | Amount | Type | Investors | Valuation |
|---|---|---|---|---|
| 05/10/21 | $8,000,000 | Series A |
Angel Physicians Fund BlueStone Venture Partners Checkmate Capital Global Health Impact Fund  IAG Capital Partners Willamette Valley Capital Wolverine Venture Fund | undisclosed |
| 11/09/23 | $80,000,000 | Series C |
Elevage Medical Technologies | undisclosed |
